2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
2
Sponsor Class
OTHER
2
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Thoracic
2
Conditions
Carcinoma, Non-Small-Cell Lung
22
Neoplasm Metastasis
6
Lung Neoplasms
5
Neoplasms
4
Carcinoma, Squamous Cell
4
Squamous Cell Carcinoma of Head and Neck
3
Recurrence
3
Brain Neoplasms
3
NSCLC
2
Head and Neck Neoplasms
2
Glioblastoma
2
Carcinoma
2
Triple Negative Breast Neoplasms
1
Thrombocytosis
1
Skin Squamous Cell Cancer
1
Rare Tumor
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Penile Neoplasms
1
Pancreatic Neoplasms
1
Non-small Cell Lung Cancer Metastatic
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Mouth Neoplasms
1
Lymphoma, Non-Hodgkin
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Chronic-Phase
1
Interventions
Pemetrexed
14
Carboplatin
13
osimertinib
11
Drug Therapy
9
aflutinib
8
Gefitinib
8
Radiotherapy
6
Docetaxel
6
Cisplatin
6
pembrolizumab
5
anlotinib
5
Radiosurgery
5
Paclitaxel
5
icotinib
4
Vinorelbine
4
Gemcitabine
4
Erlotinib Hydrochloride
4
tislelizumab
3
camrelizumab
3
apatinib
3
HM781-36B
3
toripalimab
2
spartalizumab
2
rezivertinib
2
dacomitinib
2
Tyrosine Kinase Inhibitors
2
Thalidomide
2
Surgical Procedures, Operative
2
S 1 (combination)
2
Platinum
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
NSCLC
×
dacomitinib
×
Clear all
NCT04811001
2023-02-21
CAPLAND
Fondazione Ricerca Traslazionale
Phase 2
Unknown
170 enrolled
NCT04575415
2020-10-20
BELLA
Guangdong Association of Clinical Trials
Unknown
272 enrolled